Journal of Clinical Oncology
Articles in this Issue
Comparison of adverse effect profile of PD-1 and CTLA-4 inhibitors and its variation with race and BMI.
e14620 Background: Immune checkpoint inhibitors (ICIs) are the new standard of care for treating various cancers, either alone or in combination. Cytotoxi...
Safety and efficacy of outpatient CAR-T therapy in a community-based medical center.
e19091 Background: Chimeric antigen receptor T-cell (CAR-T) therapies have transformed treatment landscape for hematologic malignancies since FDA approval...
Awareness, knowledge, and attitudes toward breast cancer polygenic risk scores for precision prevention in a multiethnic cohort of high-risk women.
10531 Background: Polygenic risk scores (PRS) have been shown to improve the risk assessment of breast cancer. Though commercially available in the US, PR...
Neoadjuvant cemiplimab with platinum-doublet chemotherapy and cetuximab in locoregionally advanced head & neck squamous cell carcinoma (HNSCC): Updated pathologic response and survival.
e18117 Background: Locoregionally advanced HNSCC treated with surgery and adjuvant radiation (RT)-based treatment is associated with significant morbidity...
Response analysis for injected and non-injected lesions and of the safety and efficacy of superficial and deep/visceral RP1 injection in the registrational cohort of anti–PD-1–failed melanoma patients of the IGNYTE trial.
9537 Background: The IGNYTE trial (NCT03767348) primary analysis of RP1 (vusolimogene oderparepvec) plusnivolumab (nivo) showed clinically meaningful dura...
Combined prognostic value of post-surgery circulating tumor DNA and tumor-stroma ratio in patients with stage III colon cancer treated with adjuvant chemotherapy.
3134 Background: Patients with stage III colon cancer (CC) are routinely treated with resection followed by adjuvant chemotherapy (ACT). About half of pat...
Investigating metabolic connectivity in patients with multiple myeloma receiving BCMA CAR T cell therapy.
7524 Background: BCMA-targeted CAR T cell therapy is a highly effective treatment for patients with relapsed/refractory multiple myeloma (MM) with side ef...
The dice of clinical trials in oncology: Strategies from mathematical permutation, combination, and theoretical oncology.
e23004 Background: With the integration of artificial intelligence and machine learning into clinical trials in oncology, the development of the oncology...
PROCEADE PanTumor: A phase 1b/2, multicenter study of precemtabart tocentecan (M9140), an anti-CEACAM5 antibody-drug conjugate (ADC) with exatecan payload, in patients with advanced solid tumors.
TPS3165 Background: CEACAM5 is a cell surface glycoprotein that is overexpressed in various carcinomas, notably in gastric cancer (GC), non-small cell lun...
MicroRNA-based signatures of early and late immune-related adverse events to anti-PD1 treatment.
2661 Background: Immune checkpoint inhibitors (ICIs) have transformed cancer treatment but are associated with toxicity in the form of immune-related adve...
Pleomorphic lobular carcinoma in situ: Upgrade rate to invasive carcinoma, association with other neoplastic processes, and clinical outcomes.
e12565 Background: Pleomorphic lobular carcinoma in situ (pleoLCIS) is a special morphologic subtype of LCIS. Data about its natural history is very limit...
Progress in the management of primary and metastatic cardiac sarcoma: Advancing multidisciplinary care in an academic sarcoma center.
e23568 Background: Cardiac sarcomas are rare tumors that are usually aggressive and associated with poor prognosis. While the optimal treatment strategy f...
Percutaneous hepatic perfusion (PHP) with melphalan for treatment of liver metastases from uveal melanoma: Initial commercial experience.
e21532 Background: Approximately 50% of patients with uveal melanoma (UM) develop metastases with the liver being the primary site of disease in > 90%...
Phase 1/2 study of TSN222, a novel dual action tumor immune agonist (DATIA), in patients with advanced malignancies.
e14572 Background: TSN222 is a novel stimulator of interferon genes (STING) agonist capable of being metabolized into a DNA synthesis inhibitor in vivo. T...
Personalized tumor-informed circulating tumor DNA as predictor of progression risk after long-term responses to immunotherapy in advanced non-small-cell lung cancer.
2547 Background: Immune checkpoint inhibitors (ICIs) have remarkably improved survival in advanced non-small-cell lung cancer (NSCLC), with about 30%～40%...
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.
4528 Background: In Phase III trials for mRCC, OS is a gold standard primary endpoint. However, for ICI-based regimens, this requires extended follow-up t...
Hospice utilization in Veterans with newly diagnosed metastatic prostate cancer.
11146 Background: Treating men with metastatic castration-sensitive prostate cancer (mCSPC) using androgen deprivation therapy (ADT), with or without trea...
Isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRd) in newly diagnosed multiple myeloma (NDMM): Outcomes in patients with 1q21+ status in the phase 3 IMROZ study.
7517 Background: Gain or amplification of 1q21 (1q21+, ≥3 copies) is a chromosomal abnormality often detected in MM that can negatively affect prognosis b...
Phase II trial of 10-day ASTX727 (decitabine/cedazuridine) in combination with venetoclax for relapsed or refractory acute myeloid leukemia.
6551 Background: The disease outcomes in relapsed refractory acute myeloblastic leukemia (R/R AML) remain dismal. We previously demonstrated safety and en...
A non-DRE, voided urine, genomic assay to diagnose prostate cancer and to assess its aggressiveness.
e17145 Background: The standard clinical practice to diagnose the presence and aggressiveness of prostate cancer, (PCa) consists of measuring serum prosta...
Improving colorectal cancer screening rates in veterans: A quality improvement initiative.
e23217 Background: Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the United States. Routine screening significantly lowe...
Prediction of site-specific immune-related adverse events of PD-L1 blockade in advanced non-small cell lung cancer through baseline organ-metastatic landscape: Pooled post-hoc analyses of two randomized controlled trials.
8542 Background: The patterns of immune-related adverse events (irAEs) during immunotherapy vary among tumors of different origins. However, it remains un...
Autologous tumor-infiltrating lymphocytes (HS-IT101) with low-dose lymphodepletion and IL-2 infusion for the treatment of advanced solid tumors: A phase I clinical trial.
TPS2674 Background: Adoptive cell therapy with tumor-infiltrating lymphocytes (TIL-ACT) has demonstrated great therapeutic potential in numerous solid tum...
Genetic characteristics and clinical outcomes of driver mutant oligometastatic non small cell lung cancer treated with combination definitive chemoradiotherapy and targeted systemic therapy.
e20676 Background: Treatment of oligometastatic non-small cell lung cancer (omNSCLC) is evolving with increasing use of local therapies to consolidate dis...
Association between alcohol intake and health-related quality of life in breast cancer survivors.
11114 Background: Advances in early detection and treatment of breast cancer (BC) have significantly improved survival outcomes. In this growing survivor...